Clinical Trial Update: 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating 64Cu-SAR-bisPSMA PET imaging for biochemical recurrence of prostate cancer; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 64Cu-SAR-bisPSMA (Copper-64-labeled SAR-bisPSMA)

Snippet

Sponsor: Clarity Pharmaceuticals Ltd | Conditions: Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy | Phase 3 | Status: RECRUITING